1418203-73-2

Basic information

• Product Name: 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde
• Synonyms: 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde
• CAS NO: 1418203-73-2
• Molecular Weight: 493.643
• Mol File: 1418203-73-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde(1418203-73-2)
• EPA Substance Registry System: 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde(1418203-73-2)

Safety Data

• Hazardous Substances Data: 1418203-73-2(Hazardous Substances Data)

Upstream product

• 616-76-2 2-hydroxy-5-formylbenzoic acid 
• 176047-66-8 benzyl 2-hydroxy-5-formylbenzoate 
• 1401791-59-0 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzoic acid 
• 1401791-58-9 benzyl 5-((R)-2-benzyl-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxopropyl)-2-propoxybenzoate 
• 1259391-06-4 benzyl 5-bromomethyl-2-propoxybenzoate 
• 1259391-05-3 benzyl 5-hydroxymethyl-2-propoxybenzoate 
• 1259391-04-2 benzyl 2-propoxy-5-formylsalicylate 

Downstream Products

• 1401791-60-3 5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxybenzaldehyde 
• 1401791-61-4 4-(1-adamantyl)-N-((5-((R)-3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-2-(cyclohexylmethyl)-3-oxopropyl)-2-propoxyphenyl)methyl)benzamide 
• 1361403-99-7 (R)-2-((3-(((4-(1-adamantyl)benzoyl)amino)methyl)-4-propoxyphenyl)methyl)-3-cyclohexylpropanoic acid 

Relevant articles and documents

Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistry-activity relationship

We previously demonstrated that the α-benzylphenylpropanoic acid-type PPARγ-selective agonist 6 exhibited a reversed stereochemistry-activity relationship, that is, the (R)-enantiomer is a more potent PPARγ agonist than the (S)-enantiomer, compared with s